Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core.


Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
15 12 2021
Historique:
received: 09 09 2021
revised: 12 11 2021
accepted: 16 11 2021
pubmed: 29 11 2021
medline: 19 1 2022
entrez: 28 11 2021
Statut: ppublish

Résumé

Tau aggregates represent a critical pathology in Alzheimer's disease (AD) and other forms of dementia. The extent of Tau neurofibrillary tangles across defined brain regions corresponds well to the observed level of cognitive decline in AD. Compound 1 (PI-2620) was recently identified as a promising Tau positron emission tomography tracer for AD and non-AD tauopathies. To evaluate the impact of the N-atom position with respect to Tau- and off-target binding, tricyclic core analogs of PI-2620 with nitrogen atoms at different positions were prepared. Affinity to aggregated Tau was evaluated using human AD brain homogenates, and their off-target binding was evaluated in a monoamine oxidase A (MAO-A) competition assay. The novel tricyclic core derivatives all displayed inferior Tau binding or MAO-A off-target selectivity, indicating PI-2620 to be the optimal design for high affinity binding to Tau and high MAO-A selectivity.

Identifiants

pubmed: 34839158
pii: S0968-0896(21)00536-8
doi: 10.1016/j.bmc.2021.116528
pii:
doi:

Substances chimiques

PI-2620 0
Pyridines 0
Radiopharmaceuticals 0
tau Proteins 0
Monoamine Oxidase EC 1.4.3.4
Nitrogen N762921K75

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

116528

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Heiko Kroth (H)

AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland. Electronic address: heiko.kroth@acimmune.com.

Felix Oden (F)

Life Molecular Imaging GmbH, Tegeler Strasse 6-7, 13353 Berlin, Germany.

Andreia Monica Serra (AM)

AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.

Jerome Molette (J)

AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.

Andre Mueller (A)

Life Molecular Imaging GmbH, Tegeler Strasse 6-7, 13353 Berlin, Germany.

Mathias Berndt (M)

Life Molecular Imaging GmbH, Tegeler Strasse 6-7, 13353 Berlin, Germany.

Francesca Capotosti (F)

AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.

Emanuele Gabellieri (E)

AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.

Heribert Schmitt-Willich (H)

Life Molecular Imaging GmbH, Tegeler Strasse 6-7, 13353 Berlin, Germany.

David Hickman (D)

AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.

Andrea Pfeifer (A)

AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland.

Ludger Dinkelborg (L)

Life Molecular Imaging GmbH, Tegeler Strasse 6-7, 13353 Berlin, Germany.

Andrew Stephens (A)

Life Molecular Imaging GmbH, Tegeler Strasse 6-7, 13353 Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH